MAPT and Alzheimer disease: To test the potential therapeutic impact of Chk1 inhibition in AD, we used less toxic and more potent second-generation Chk1 inhibitor GDC-0575 [25, 26] (MCE, HY-112167) to treat cultured HEK293/tau cells and N2a/APP cells.